Equities Analysts Offer Predictions for BEAM Q3 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Research analysts at HC Wainwright lowered their Q3 2026 EPS estimates for shares of Beam Therapeutics in a report released on Friday, August 7th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($1.25) per share for the quarter, down from their prior forecast of ($1.01). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.37) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q4 2026 earnings at ($1.29) EPS, FY2026 earnings at ($4.64) EPS, Q1 2027 earnings at ($1.25) EPS, Q2 2027 earnings at ($1.27) EPS, Q3 2027 earnings at ($1.21) EPS, Q4 2027 earnings at ($1.25) EPS, FY2027 earnings at ($5.08) EPS, FY2028 earnings at ($3.83) EPS, FY2029 earnings at ($2.71) EPS and FY2030 earnings at ($1.61) EPS.

Beam Therapeutics (NASDAQ:BEAM) last posted its earnings results on Tuesday, August 4th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.07). Beam Therapeutics had a negative return on equity of 30.71% and a negative net margin of 54.75%.The firm had revenue of $0.49 million during the quarter, compared to the consensus estimate of $16.37 million. During the same quarter in the previous year, the company earned ($1.00) EPS. The business’s revenue was down 94.2% compared to the same quarter last year.

Several other brokerages have also issued reports on BEAM. Wall Street Zen lowered shares of Beam Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Bank of America reiterated a “buy” rating and issued a $47.00 price objective on shares of Beam Therapeutics in a research note on Wednesday, July 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Beam Therapeutics in a report on Friday, July 17th. Sanford C. Bernstein decreased their target price on Beam Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Finally, Tudor Pickering set a $39.00 target price on Beam Therapeutics in a research note on Wednesday, May 13th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Beam Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $49.00.

Beam Therapeutics Stock Down 0.7%

BEAM stock opened at $27.28 on Tuesday. The stock’s fifty day simple moving average is $30.54 and its two-hundred day simple moving average is $28.93. The company has a current ratio of 14.57, a quick ratio of 14.57 and a debt-to-equity ratio of 0.09. Beam Therapeutics has a 1-year low of $15.60 and a 1-year high of $38.26. The stock has a market cap of $2.82 billion, a P/E ratio of -31.72 and a beta of 2.23.

Insider Activity at Beam Therapeutics

In other Beam Therapeutics news, insider Fmr Llc sold 251,488 shares of Beam Therapeutics stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $35.26, for a total transaction of $8,867,466.88. Following the completion of the sale, the insider directly owned 854,583 shares in the company, valued at $30,132,596.58. The trade was a 22.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Amy Simon sold 16,667 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $25.74, for a total transaction of $429,008.58. Following the completion of the transaction, the insider directly owned 85,696 shares of the company’s stock, valued at approximately $2,205,815.04. This represents a 16.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 301,527 shares of company stock worth $10,468,500. 3.80% of the stock is owned by company insiders.

Institutional Trading of Beam Therapeutics

Hedge funds have recently made changes to their positions in the stock. Concurrent Investment Advisors LLC bought a new stake in shares of Beam Therapeutics in the 4th quarter valued at about $2,130,000. Baillie Gifford & Co. grew its holdings in shares of Beam Therapeutics by 39.8% in the fourth quarter. Baillie Gifford & Co. now owns 416,224 shares of the company’s stock worth $11,538,000 after purchasing an additional 118,421 shares during the last quarter. Canal Insurance CO purchased a new position in shares of Beam Therapeutics in the first quarter worth $953,000. Ishara Investments LP purchased a new position in shares of Beam Therapeutics in the fourth quarter worth $1,386,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Beam Therapeutics during the 1st quarter valued at $1,267,000. 99.68% of the stock is owned by institutional investors.

Trending Headlines about Beam Therapeutics

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating despite lowering estimates, indicating the firm continues to see long-term value in Beam’s base-editing platform and pipeline.
• Positive Sentiment: J.P. Morgan also maintained its Buy rating on Beam, providing some support for the bullish long-term investment thesis. J.P. Morgan Sticks to Its Buy Rating for Beam Therapeutics
• Neutral Sentiment: HC Wainwright’s updated forecasts call for losses of $4.64 per share in fiscal 2026, $5.08 in fiscal 2027, $3.83 in fiscal 2028, $2.71 in fiscal 2029 and $1.61 in fiscal 2030. The estimates still imply improving results after 2027, but profitability remains distant.
• Negative Sentiment: The firm cut its fiscal 2026 loss forecast from $3.95 to $4.64 per share and its fiscal 2027 loss forecast from $3.86 to $5.08 per share. It also reduced estimates for each quarter from the third quarter of 2026 through the fourth quarter of 2027.
• Negative Sentiment: Longer-term revisions were also unfavorable: the projected fiscal 2028 loss widened from $2.78 to $3.83 per share, fiscal 2029 from $2.09 to $2.71, and fiscal 2030 from $1.46 to $1.61. These cuts reinforce concerns about higher development costs, continued cash burn and delayed earnings improvement.

Beam Therapeutics Company Profile

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.